FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvalsAppointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development HEIDELBERG, Germany, June 02, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or "the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) m